Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIs
Author:
Affiliation:
1. Oncology Department of Beijing Chest Hospital, Capital Medical University
2. Pathology Department of Beijing Chest Hospital, Capital Medical University
3. Oncology Department of Beijing Friendship Hospital, Capital Medical University
Abstract
Background The mechanism of secondary drug resistance in advanced Non Small Cell Lung Cancer(NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) gene sensitive mutation after EGFR-Tyrosine Kinase Inhibitors (TKIs) is complex. Acquired Anaplastic Lymphoma Kinase (ALK) fusion mutation is a rare type, and there are few reports on the clinical characteristics and treatment options for this group of patients. Methods Cases of 820 locally advanced or metastatic EGFR-sensitive mutations NSCLC patients whose gene status were detected by Next Generation Sequencing(NGS)after EGFR-TKIs resistance were retrospectively collected. Acquired ALK fusion gene mutation occurred in 4 of them. The clinical information, pathological types, gene mutation status, treatment plans, efficacies and prognoses of these 4 cases were analyzed. Results All 4 patients had lung adenocarcinoma. Three had EML4-ALK fusion and 1 had STRN-ALK fusion. EGFR gene mutation was detected negative in 2 cases after drug resistance, and the abundance of EGFR gene mutation decreased in 2 cases. The Progression Free Survival (PFS) of EGFR-TKIs ranged from 6 to 21 months, and after acquired ALK mutation objective response was all achieved using ALK-TKIs alone or the combination of ALK-TKIs and EGFR-TKIs, with PFS all exceeding 6 months. One patient developed small cell lung cancer transformation after ALK-TKIs resistance. Conclusion Acquired ALK fusion as a resistant mechanism of EGFR-TKIs is present and rare. EGFR is undetectable or abundance decreased when ALK fusion emerges. ALK-TKIs alone and ALK-TKIs combined with EGFR-TKIs are alternative treatment choices.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Multiple primary lung cancer: A literature review;Romaszko AM;Adv Clin Exp Med,2018
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021
3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch TJ;N Engl J Med,2004
4. Epidermal growth factor receptor mutations in lung cancer;Sharma SV;Nat Rev Cancer,2007
5. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer;Soria J-C;N Engl J Med,2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3